^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

NGM936

i
Other names: NGM936
Associations
Trials
Company:
NGM Biopharma
Drug class:
CD3 agonist, ILT-3 inhibitor
Related drugs:
Associations
Trials
2years
Preclinical Characterization of NGM936, a Novel Bispecific T Cell Engager Targeting ILT3 for the Treatment of Acute Myeloid Leukemia with Monocytic Differentiation (ASH 2022)
In both whole blood cytokine release assays and in TDCC assays in which cytokine secretion was measured after target engagement, induction of TNF-α, IL-6, IFN-γ, and IL-2 by NGM936 was considerably lower than that induced by a vibecotamab biosimilar (CD123 x CD3). Finally, NGM936 induced a dose-dependent depletion of circulating tumor cells in a xenograft model in which irradiated, immunodeficient NSG mice were engrafted with human PBMCs and human ILT3+ AML cells. NGM936 thus represents a promising new treatment strategy for monocytic AML, with the potential to eliminate monocytic leukemia cells while minimizing the myelotoxicity associated with ablation of healthy bone marrow.
Preclinical
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD34 (CD34 molecule) • IL2 (Interleukin 2)
|
vibecotamab (XmAb14045) • NGM936
2years
A Novel Bi-Specific T-Cell Engager Targeting ILT3 Is Potently Effective in Multiple Myeloma (ASH 2022)
Our work represents the first evidence and rationale for clinical development of NGM936 surrogate antibody an ILT3-targeted immunotherapy as a viable therapeutic approach for MM cell killing. These data suggest that targeting ILT3 is an effective and safe therapeutic approach in MM.
IO biomarker
|
CASP3 (Caspase 3) • CASP7 (Caspase 7)
|
Chr t(14;16)
|
NGM936